Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials.

ABSTRACT:

Objective

Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment but can cause several immune-related adverse events. Case reports and population-based studies have reported that ICI treatment may also be associated with higher incidence of fractures, but this has not been systematically studied. The aim of the study is to examine whether treatment with ICIs increases the incidence of fractures compared with chemotherapy or placebo.

Methods and analysis

Electronic databases (PubMed, Embase and Cochrane Library) were systematically searched for randomised controlled trials (RCTs), including an ICI monotherapy arm and a placebo/chemotherapy arm, published from database inception to December 2024. Only patients with solid tumours were included. The review prot

SUBMITTER: Yavropoulou MP 

PROVIDER: S-EPMC12658493 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature